Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Artelo Biosciences ( (ARTL) ) has shared an announcement.
On January 30, 2026, Artelo Biosciences reconvened its previously adjourned Annual Meeting of Stockholders, achieving a quorum with approximately 50.4% of outstanding common shares represented. Shareholders re-elected Douglas Blayney, M.D., and Connie Matsui as Class II directors to serve until the 2028 annual meeting, approved on an advisory basis the executive compensation package for the company’s named executive officers, and ratified Malone Bailey LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, thereby confirming support for current board composition, pay practices, and audit oversight.
The most recent analyst rating on (ARTL) stock is a Sell with a $1.50 price target. To see the full list of analyst forecasts on Artelo Biosciences stock, see the ARTL Stock Forecast page.
Spark’s Take on ARTL Stock
According to Spark, TipRanks’ AI Analyst, ARTL is a Neutral.
The score is driven primarily by weak financial performance (no revenue, widening losses, sustained cash burn) and the shift to negative equity, which heightens financing and solvency risk. Technicals are only neutral-to-weak with a depressed longer-term trend, while valuation offers little support due to negative earnings and no dividend. Corporate events add further downside risk from Nasdaq compliance/delisting uncertainty.
To see Spark’s full report on ARTL stock, click here.
More about Artelo Biosciences
Average Trading Volume: 646,932
Technical Sentiment Signal: Sell
Current Market Cap: $3.65M
See more insights into ARTL stock on TipRanks’ Stock Analysis page.